amifostine

Seventy male C57BL/6J mice (6-8 weeks old) were categorized into five groups: a normal control group (Con), an irradiation-only group (IR), groups administered low-dose BA prior to and following irradiation (IR+BA-L, 100 mg/kg bw), a high-dose BA group (IR+BA-H, 200 mg/kg bw), and a group receiving the clinical radiation protection agent amphotericin (IR+WR-2721, 30 mg/kg bw)...FMT experiments further validate that BA's protective action depends on gut microbiota regulation. The findings suggest that BA, as a gut microbiota-modulating agent, holds promise for preventing and treating RIII.

P1/2, N=36, Recruiting, Xerient Pharma | Not yet recruiting --> Recruiting

Skin toxicity is common in rectoanal cancer radiotherapy and linked to tumor, treatment, and patient factors. Optimized techniques (e.g., VMAT) combined with spray-type protectants enable precision management, improving outcomes.

Conversely, low ALP expression in tumor cells cannot realize effective cytoprotection, causing AFe-NPC to induce immunogenic ferroptosis. AFe-NPC-induced ferroptosis can boost CD8+ T cell-mediated systemic anticancer immunity and synergize with immune checkpoint blockade to eradicate primary and metastatic tumors.

Black garlic extract confers protection against cisplatin-induced AKI by enhancing renal antioxidant defenses and mitigating oxidative stress-related damage. These findings support its potential as a complementary approach for preventing nephrotoxicity during cisplatin therapy.

Radioprotectors like antioxidants and amifostine safeguard normal tissues...Key findings highlight nanotechnology's role in enhancing radiosensitization via dose enhancement factors and synergistic therapies. Implications include personalized treatments tailored to tumor biology, the reduction of radioresistance through precision medicine and data-driven strategies, and ultimately, the improvement of radiotherapy efficacy and patient outcomes.

Despite these structural improvements, mRNA levels of AQP5, AMY1, and hyaluronic acid synthase remained unchanged, suggesting that functional decline had not yet fully manifested at this early stage. These findings indicate that amifostine and melatonin provide partial radioprotection against acute fibrotic and structural damage in laryngeal tissues, supporting their potential as adjunctive agents for preserving vocal and mucosal functions during radiotherapy.

Management strategies incorporate neuroprotective agents (e.g., amifostine), cognitive rehabilitation, and non-invasive neuromodulation techniques...A multidisciplinary and anticipatory approach is essential for preserving neurological function and enhancing quality of life across the cancer continuum. Advances in diagnostics and therapeutics are reshaping the integration of neurophysiology within comprehensive cancer care.

Initially, we performed molecular docking to evaluate the binding affinity of MeJA against the caspase-3, cyclooxygenase-2 (COX-2), and nuclear factor kappa B (NF-κB) proteins in the presence of the reference drug amifostine. These findings collectively highlight the therapeutic potential of MeJA in alleviating cisplatin-induced nephrotoxicity through modulation of apoptosis and inflammatory pathways. MeJA may serve as a promising nephroprotective agent, warranting further clinical investigation for its potential application in oncology settings.

In contrast, there was a decrease in necrotic tubules, degenerative Bowman's capsules, and the levels of MDA, Cleaved Caspase-3, and 8-OHdG in the amifostine and dexmedetomidine 100 µg/kg and 200 µg/kg treatment groups (p ≤ 0.05). Alpha 2 adrenergic receptor agonists exhibit protective effects against kidney injury induced in association with x-irradiation by reducing oxidative stress and apoptosis.

Histopathological evaluation revealed reduced MMP-2 and MMP-9 immunopositivity in the PGPE250 and PGPE500 groups. These findings highlight the lung-protective properties of PGPE, underscoring its potential as a therapeutic agent for sepsis-induced acute lung injury.

The role of several radioprotective agents, including amifostine, N-acetylcysteine, tempol, manganese superoxide dismutase (MnSOD) plasmid liposomes, vitamin E, and beta-carotene has been analyzed with a focus on their logistical applications in breast reconstruction. Despite several challenges, the integration of radioprotective agents into post-mastectomy radiotherapy protocols offers significant potential to improve reconstructive outcomes. Development of novel radioprotective agents with improved selectivity and fewer side effects and large-scale clinical trials in diverse group of patients are warranted to determine long-term safety and efficacy.